Hemp Enforcement, Modernization, and Protection Act

Bill Number

H.R. 7212

Origin Chamber

House

Congress

119th Congress, Session 2

Policy Area

Health

Status

Introduced

Latest Action

2026-01-22: Referred to the House Committee on Energy and Commerce.

Last Updated

2026-06-03T08:07:25Z

AI-Generated Summary

Summary of H.R. 7212: Hemp Enforcement, Modernization, and Protection Act

Purpose

This bill amends the Federal Food, Drug, and Cosmetic Act (FD&C Act) to establish a federal regulatory framework for cannabinoid hemp products—articles containing cannabinoids (chemical compounds from cannabis like CBD or Delta-8 THC) intended for human or animal use on or in the body. It aims to ensure safety, proper labeling, and manufacturing standards while excluding FDA-approved drugs, devices, and certain other products.

Key Provisions

• Definitions (Sec. 3): Broadly defines cannabinoid (e.g., CBD, Delta-9/8 THC, synthetics); cannabinoid hemp product (excludes approved drugs/devices/food additives); subtypes (oral, inhalable, topical); prohibited cannabinoid product (e.g., exceeds potency limits, synthetics, for food animals).
• New Chapter X in FD&C Act (Sec. 4):
• Adulteration (Sec. 1002): Products are adulterated if contaminated, exceed limits, contain additives like caffeine/melatonin, or fail type-specific standards.
• Misbranding (Sec. 1003): Requires detailed labeling (e.g., ingredients, cannabinoid content, QR code for testing, risk disclaimers, no health claims); child-resistant packaging; no kid-appealing designs.
• Type-Specific Standards:

| Type | Key Rules | |------|-----------| | Oral (e.g., edibles, oils) | Serving/package limits; single-serve liquids or measuring devices. | | Inhalable (e.g., vapes) | Pesticide-free; limited additives/flavors; prefilled non-refillable cartridges; pre-market notification. | | Topical (e.g., creams) | Potency limits; no systemic absorption intent. |

• Minimum Age: No sales to under 21 (Sec. 1007).
• Manufacturing/Testing (Sec. 1008): Uniform FDA standards for contaminants/cannabinoids.
• Registration/Listing (Sec. 1009): Facilities (domestic/foreign) register biennially; products listed with formulations/labels.
• Inspections/Recalls (Secs. 1010-1011): Foreign facility checks; mandatory recalls for serious risks.
• Potency Thresholds (Sec. 1012): FDA sets limits (e.g., default: 10mg intoxicating cannabinoids/serving oral); rulemaking within 3 years.
• Advisory Committee (Sec. 1013): 16 members (experts, industry reps) advises on limits/safety.
• Enforcement (Sec. 5): Adds prohibited acts (e.g., selling prohibited products, to minors); enhanced penalties (up to 10 years prison); seizure authority.
• Rules of Construction (Sec. 6): Does not limit existing FDA powers.

Significant Changes to Existing Law

• Post-2018 Farm Bill: Creates first comprehensive FDA oversight for hemp-derived consumer products (previously unregulated federally beyond 0.3% Delta-9 THC crop limit).
• Integrates into FD&C Act like food/cosmetics but with tailored rules (e.g., no dietary supplement claims; potency caps on intoxicating types like Delta-8).
• Excludes raw hemp plants under cultivation; carves out approved drugs/devices.
• Mandates registration/listing (similar to food facilities) and pre-market reports for inhalables.

Potential Impacts

• Government Agencies: FDA gains major new duties (rules, inspections, recalls, committee); requires resources/timeline (e.g., thresholds rule in 3 years).
• Citizens/Consumers: Improved safety/transparency (testing, labels, recalls); restricted access (age 21+, potency limits, no high-risk additives); protects vulnerable groups (pregnant, kids).
• Industry: Legitimizes market but imposes compliance (registration, testing, labeling); bans some products (synthetics, animal food use); phased implementation (1 year for existing).
• International Relations: Enables foreign facility inspections; blocks imports from non-compliant countries.

Main Stakeholders Affected

• Hemp/Cannabinoid Industry: Manufacturers, processors, importers, retailers (must register, test, label; face enforcement).
• Consumers: Human users (safer products, age limits); animal owners (limited options).
• Farmers/Growers: Raw hemp unaffected if compliant.
• FDA/HHS: Oversees implementation/enforcement.
• States: Advisory input; aligns with federal standards.
• Retailers: Age verification; no sales of prohibited items.

Notable Legal, Constitutional, or Political Implications

• Legal: Clarifies hemp products are neither foods nor supplements; strengthens FDA adulteration/misbranding tools; preempts some state variations via interstate commerce rules.
• Constitutional: Relies on Commerce Clause for regulation; no apparent free speech issues (disclaimers over claims).
• Political: Bipartisan sponsors (Reps. Griffith, Veasey); balances industry growth with public health post-legalization; potential for industry lawsuits if thresholds delay.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Griffith, H. Morgan [R-VA-9]

Cosponsors (7)

Rep. Veasey, Marc A. [D-TX-33], Rep. Crenshaw, Dan [R-TX-2], Rep. Garcia, Sylvia R. [D-TX-29], Rep. Vindman, Eugene Simon [D-VA-7], Rep. Baird, James R. [R-IN-4], Rep. James, John [R-MI-10], Rep. Grijalva, Adelita S. [D-AZ-7]

Recent Actions

• 2026-01-22: Referred to the House Committee on Energy and Commerce.
• 2026-01-22: Introduced in House
• 2026-01-22: Introduced in House

Bill Versions

• Hemp Enforcement, Modernization, and Protection Act — issued 2026-01-22 — PDF (58 pages)